Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-247550 (Ixabepilone) in Metastatic Colorectal Cancer
NCT00033306Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2002
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in metastatic colorectal cancer (mCRC), sponsored by University of Alabama at Birmingham. Primary endpoint: Tumor Response Rate. Started Feb 2002; status: terminated.
02
Drugs
ixabepilone
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00033306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033306.